Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract
Status:
Terminated
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
This research study is studying a combination of two experimental drugs as a possible
treatment for Bladder Cancer that recurred after treatment with standard therapy, or Bladder
Cancer that got worse while on treatment with standard therapy.
The following interventions will be involved in this study:
- B-701
- Pembrolizumab
Phase:
Phase 1
Details
Lead Sponsor:
Dana-Farber Cancer Institute Mark Pomerantz, MD
Collaborators:
BioClin Therapeutics, Inc. Merck Sharp & Dohme Corp. Rainier Therapeutics